ClinicalTrials.gg
CompletedNCT01847092Updated May 27, 2020Results posted

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

A Phase 2 interventional study of AZD1722 and Placebo in Chronic Kidney Disease and Type 2 Diabetes Mellitus, sponsored by Ardelyx. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-05-27.

Sponsored by Ardelyx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
265th of 819
154 · median 72
Started
2013
with 45 others
Phase 2
156 of 988
22 open now
Registered
298th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 265th largest by enrollment of the 819 interventional ones that give a count, is one of 46 that started in 2013, is one of 156 in phase 2, and was the 298th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.

03

Conditions studied

  • Chronic Kidney Disease
  • Type 2 Diabetes Mellitus

Keywords

  • albuminuria
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged 18 to 80 years, inclusive.
  • between 18 and 45 kg/m2, inclusive.
  • Type 2 diabetes mellitus and receiving ≥1 glucose lowering medication for at least 3 months prior to randomization
  • Stage 3 CKD
  • MSSBP ≥130 mmHg
  • Urinary albumin: mean UACR ≥ 200 mg/g

Exclusion criteria

Exclusion Criteria:

  • Urinary albumin: UACR > 3500 mg/g
  • History of a renal transplant
  • MSSBP >180 mmHg or a MSDBP of >120 mmHg on two occasions during screening or run-in periods
  • History of inflammatory bowel disease or diarrhea predominant irritable bowel syndrome
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Active comparator
    AZD1722

    AZD1722 in 5, 15, 30, or 60 mg capsules. Starting dose is 15 mg BID PO for 12 Weeks

    Drug: AZD1722

  • Placebo comparator
    Placebo

    Placebo capsule BID PO for 12 Weeks

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo for AZD1722

06

What researchers measure

Primary outcomes

  1. Changes in Urine Albumin to Creatinine Ratio (UACR)

    The difference between tenapanor and placebo in the change in UACR from baseline to the end of 12 weeks of treatment

    Time frame: Week 12

Secondary outcomes

  1. Change in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint

    Time frame: 12 weeks

07

Results

Posted May 27, 2020

Participant flow

Participant flow — Overall Study
MilestoneAZD1722Placebo
Started7777
Completed5166
Not completed2611
Withdrew: Adverse event123
Withdrew: Withdrawal by subject55
Withdrew: Protocol specified80
Withdrew: Physician decision11
Withdrew: Protocol violation02

Outcome measures

PrimaryChanges in Urine Albumin to Creatinine Ratio (UACR)

The difference between tenapanor and placebo in the change in UACR from baseline to the end of 12 weeks of treatment

Time frame:
Week 12
Reported as:
Mean · mg/g
Changes in Urine Albumin to Creatinine Ratio (UACR)
mg/gAZD1722Placebo
Changes in Urine Albumin to Creatinine Ratio (UACR)-64.6 ± 898.4104.8 ± 668.0
Statistical analysis
  • AZD1722 vs Placebo · Mixed Models Analysis · p = 0.279
SecondaryChange in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint
Time frame:
12 weeks
Reported as:
Least squares mean · mL/min/1.73 m2
Change in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint
mL/min/1.73 m2AZD1722Placebo
Change in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint-2.8 ± 1.21-2.7 ± 1.19
Statistical analysis
  • AZD1722 · ANCOVA · p = 0.94

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD17220/77 (0%)3/77 (3.9%)45/77 (58.4%)
Placebo0/77 (0%)2/77 (2.6%)4/77 (5.2%)
Most frequent serious events
Most frequent serious events
EventAZD1722Placebo
HyperkalemiaInvestigations2/771/77
Deep Vein ThrombosisBlood and lymphatic system disorders1/770/77
Cardiac failure congestiveCardiac disorders0/771/77
Most frequent other events
Most frequent other events
EventAZD1722Placebo
DiarrheaGastrointestinal disorders45/774/77

Baseline characteristics

Age, Continuous
Age, Continuous(years)AZD1722PlaceboTotal
Mean64.6 ± 8.7965.6 ± 8.7765.1 ± 8.77
Sex: Female, Male
Sex: Female, Male(Participants)AZD1722PlaceboTotal
Female5252104
Male252550
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AZD1722PlaceboTotal
Hispanic or Latino181937
Not Hispanic or Latino5958117
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AZD1722PlaceboTotal
American Indian or Alaska Native101
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American211839
White5353106
More than one race000
Unknown or Not Reported145
08

Study locations

1 site
  • Creekside Endocrine Associates PC
    Denver, Colorado 80209, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Mar 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2020, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2013
First posted
May 6, 2013
Start
May 2013
Primary completionActual
Mar 2015
CompletionActual
Apr 2015
Results first posted
May 27, 2020
Last update
May 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01847092
Lead sponsor
Ardelyx
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
May 6, 2013
Start date
May 2013
Primary completion
Mar 2015
Completion
Apr 2015
Results posted
May 27, 2020
Last update
May 27, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion